Semax

At a glance

Standard Protocol

Alternative: Acute Recovery

Nootropic protocols are state-dependent: sleep, anxiety, stimulants, psychiatric history, and route can change the response. The logic is morning-biased, low-entry dosing, and stopping if arousal or mood destabilizes. Entry context: target (TrkB; MC4R); route Subcutaneous; timing Morning. Unapproved or source-dataset dosing tables are hypotheses, not recommendations. FDA/safety flags lower confidence and raise the evidence bar for any claimed benefit. Compatibility is conditional: a reasonable solo compound can become inappropriate once a contraindicated partner is added.

• Over-stimulation and irritability: the most commonly reported adverse effect; mild to moderate CNS stimulation, particularly with doses above 300mcg; characterized by restlessness, mild agitation, and shortened patience; typically dose-dependent and resolves with dose reduction.
• Insomnia: MC4R activation increases arousal state; morning dosing is mandatory; any dose taken after noon risks sleep onset difficulty that evening.
• Mild tachycardia: adrenergic-adjacent stimulation from MC4R activation produces a slight elevation in resting heart rate in some subjects; usually mild and transient.
• Anxiety exacerbation: subjects with baseline anxiety disorders may experience worsening of anxiety symptoms; paradoxical given the BDNF/TrkB neuroprotective activity but consistent with the stimulant-like MC4R component.
• Hair shedding (rare): BDNF elevation from Semax can accelerate hair follicle cycling, transiently shifting follicles from anagen (growth) into catagen/telogen (shedding) phase; typically reversible as BDNF normalizes post-cycle.
• Mild headache: reported in initial days of use; may reflect cerebrovascular response to MC4R-driven changes in neurovascular tone.
• Nasal irritation: relevant with intranasal formulations; not applicable to subcutaneous administration.
• Appetite suppression: MC4R agonism in the hypothalamus has mild anorexigenic effects; generally not clinically significant at standard doses but notable in underweight individuals.
• TrkB/MC4R receptor downregulation with prolonged continuous use: the mechanistic basis for the cycle/washout protocol; persistent receptor agonism without recovery periods reduces receptor density and diminishes subsequent cycle efficacy.

• Concurrent Adamax use: Adamax is a potentiated derivative of Semax sharing the same TrkB/MC4R/BDNF mechanism; co-administration produces redundant receptor overstimulation without additional therapeutic benefit and significantly increases anxiety, cardiovascular stimulation, and insomnia risk; these compounds are mutually exclusive and should never be used simultaneously.
• Severe anxiety disorders, generalized anxiety disorder (GAD), or panic disorder: Semax's MC4R activation and dopaminergic enhancement can meaningfully worsen anxiety symptomatology in predisposed subjects; baseline anxiety must be well-controlled before initiating.
• Active manic episode or bipolar I disorder during manic phase: Semax's stimulant-adjacent nootropic activity and dopaminergic enhancement can trigger or accelerate manic symptoms in susceptible individuals.
• Active psychotic disorders (schizophrenia, schizoaffective disorder): MC4R and dopaminergic pathway stimulation is contraindicated during active psychosis.
• Severe uncontrolled hypertension: Semax produces mild adrenergic activation as a secondary effect of MC4R agonism; not a primary cardiovascular concern but warrants caution in severely hypertensive subjects.
• Known hypersensitivity to Semax or ACTH-derived peptides.
• Pregnancy: no human safety data; ACTH-derived peptide activity during pregnancy is not established as safe.
• Breastfeeding: insufficient safety data.
• Concurrent use with MAOIs: additive dopaminergic and serotonergic potentiation creates serotonin syndrome risk.

Synergistic / related

• https://the source dataset.com/peptide-codex.php
• https://www.fda.gov/drugs/guidance-compliance-regulatory-information/human-drug-compounding
• https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks?pg=3
• https://pubmed.ncbi.nlm.nih.gov/?term=Semax